← Back to patent-cliff list
Surufatinib
Tier C — Watch / tradeSurufatinib
-
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR1, CSF1R, VEGFR
Brand：SULANDA
Indications (approved)：Neuroendocrine tumour
Regional status
US
Phase I
2020-07-09
EU
Discontinued
2015-11-01
China
Approved
2020-12-29
Japan
Phase II
2021-09-02
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Surufatinib?
Approved indications include: Neuroendocrine tumour.
When does the Surufatinib patent expire?
No public expiry year is available for Surufatinib yet; this page updates once verified.
How do I get a quote for Surufatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27